As the U.S. stock market wraps up a strong year with a slight downturn, major indices like the Dow Jones Industrial Average and S&P 500 have experienced notable monthly losses despite impressive annual gains. In this context of fluctuating performance, identifying undervalued stocks becomes crucial for investors aiming to capitalize on potential market inefficiencies and intrinsic value discrepancies.
Name | Current Price | Fair Value (Est) | Discount (Est) |
First Solar (NasdaqGS:FSLR) | $176.24 | $350.71 | 49.7% |
Camden National (NasdaqGS:CAC) | $42.74 | $84.45 | 49.4% |
Ally Financial (NYSE:ALLY) | $36.01 | $71.71 | 49.8% |
HealthEquity (NasdaqGS:HQY) | $95.95 | $189.22 | 49.3% |
Kanzhun (NasdaqGS:BZ) | $13.80 | $26.99 | 48.9% |
LifeMD (NasdaqGM:LFMD) | $4.95 | $9.82 | 49.6% |
Mr. Cooper Group (NasdaqCM:COOP) | $96.01 | $188.12 | 49% |
Progress Software (NasdaqGS:PRGS) | $65.15 | $129.60 | 49.7% |
South Atlantic Bancshares (OTCPK:SABK) | $15.94 | $30.95 | 48.5% |
Repligen (NasdaqGS:RGEN) | $143.94 | $280.90 | 48.8% |
Click here to see the full list of 174 stocks from our Undervalued US Stocks Based On Cash Flows screener.
Here's a peek at a few of the choices from the screener.
Overview: CyberArk Software Ltd. develops, markets, and sells software-based identity security solutions and services globally, with a market cap of approximately $13.93 billion.
Operations: The company generates revenue from its Security Software & Services segment, amounting to $909.46 million.
Estimated Discount To Fair Value: 29.8%
CyberArk Software is trading at US$333.15, significantly below its estimated fair value of US$474.53, suggesting it may be undervalued based on cash flows. The company's earnings and revenue are projected to grow faster than the US market, with earnings expected to increase by 32.3% annually. Recent product innovations like FuzzyAI and strategic partnerships enhance its growth potential despite a recent follow-on equity offering that could dilute shares further.
Overview: iRhythm Technologies, Inc. is a digital healthcare company that designs, develops, and commercializes device-based technology for ambulatory cardiac monitoring services to diagnose arrhythmias in the United States, with a market cap of approximately $2.72 billion.
Operations: The company's revenue is primarily generated from its Medical Labs & Research segment, which amounts to $560.03 million.
Estimated Discount To Fair Value: 24.1%
iRhythm Technologies is trading at US$90.17, below its estimated fair value of US$118.81, indicating potential undervaluation based on cash flows. Despite recent insider selling and shareholder dilution, the company forecasts revenue growth of 15.1% annually, surpassing the broader US market's growth rate. The FDA clearance for enhancements to its Zio AT device could bolster future performance as iRhythm aims for profitability within three years amidst strong product compliance and physician agreement metrics.
Overview: monday.com Ltd. develops software applications globally, including in the United States, Europe, the Middle East, Africa, and the United Kingdom, with a market cap of approximately $11.73 billion.
Operations: The company generates revenue of $906.59 million from its Internet Software & Services segment.
Estimated Discount To Fair Value: 30.8%
monday.com, trading at US$235.44, is undervalued by over 30% based on cash flow estimates with a fair value of US$340.01. Despite past shareholder dilution and a recent net loss of US$12.03 million in Q3 2024, its revenue grew to US$251 million from the previous year and is forecasted to grow significantly faster than the market at over 20% annually, driven by strategic expansions and potential M&A activities.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NasdaqGS:CYBR NasdaqGS:IRTC and NasdaqGS:MNDY.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.